Dow Jones
33.926,01 -127,89 (-0,38%) Nasdaq
12.006,96 -193,84 (-1,59%) Nikkei 225
27.693,65 +184,19 (+0,67%) EUR/USD
1,0798 +0,0001 (+0,01%) BTC-EUR
21.152,90 -661,44 (-3,03%) CMC Crypto 200
524,64 -12,22 (-2,28%)
Cellectis S.A. (0WA2.L)
| Chiusura precedente | 2,7180 |
| Aperto | 2,6542 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 2,3514 - 2,4300 |
| Intervallo di 52 settimane | 2,3514 - 2,4300 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,85 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, in accordance with French regulatory requirements, is supplementing its previous announcement of the pricing of its underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (“ADS”), each representin
- GlobeNewswire
Cellectis Announces Pricing of Follow-On Offering
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces the pricing of its previously announced underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (“ADS”), each representing the right to receive one ordinary share of Cellectis, nominal va
- GlobeNewswire
Cellectis Announces Launch of Follow-On Offering
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the launch of a global offering of USD 22 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis, nominal value €0.05 per share (the “Global Offering”) pursuant to an underwriti
